- Likelihood interval for nonlinear regression
-
Lee MH, Bae KS
- KMID: 2552409
- Transl Clin Pharmacol.
- 2023 Jun;31(2):85-94.
- doi: 10.12793/tcp.2023.31.e8
Wald confidence interval has been used as the conventional method of interval estimation for the parameters in nonlinear models. Because Wald confidence interval is symmetric around the point estimate, it... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of pharmacokinetic drugdrug interaction between tegoprazan and clarithromycin in healthy subjects
-
Oh M, Lee H, Kim S, Kim B, Song GS, Shin JG, Ghim JL
- KMID: 2552412
- Transl Clin Pharmacol.
- 2023 Jun;31(2):114-123.
- doi: 10.12793/tcp.2023.31.e11
Tegoprazan is a novel potassium-competitive acid blocker that treats gastric acid-related diseases. Clarithromycin was widely used as one of various regimens for eradicating Helicobacter pylori. This study compared the pharmacokinetic... -
- CITED
-
- Close
- SHARE
-
- Close
- A review of the Bayesian approach with the MCMC and the HMC as a competitor of classical likelihood statistics for pharmacometricians
-
Choi K
- KMID: 2552408
- Transl Clin Pharmacol.
- 2023 Jun;31(2):69-84.
- doi: 10.12793/tcp.2023.31.e9
This article reviews the Bayesian inference with the Monte Carlo Markov Chain (MCMC) and the Hamiltonian Monte Carlo (HMC) samplers as a competitor of the classical likelihood statistical inference for... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety and pharmacokinetic comparison between fenofibric acid 135 mg capsule and 110 mg entericcoated tablet in healthy volunteers
-
Seo YB, Kim JH, Song JH, Jung W, Nam KY, Kim N, Choi YW, Cho S, Ki DH, Lee HJ, Moon J, Lee S, Kim J, Hong JH, Jung S, Jung JG
- KMID: 2552410
- Transl Clin Pharmacol.
- 2023 Jun;31(2):95-104.
- doi: 10.12793/tcp.2023.31.e7
This study aimed to compare the pharmacokinetic (PK) and safety profiles of 2 fenofibric acid formulations under fasting and fed conditions. The reference was a 135 mg capsule, while the... -
- CITED
-
- Close
- SHARE
-
- Close
- Fed and fasted bioequivalence assessment of two formulations of extended-release fixed-dose combination dapagliflozin/metformin (10/1,000 mg) tablets in healthy subjects
-
Lee HW, Kang WY, Park JS, Lee JH, Gwon MR, Yang DH, Kim EH, Park SJ, Yoon YR, Seong SJ
- KMID: 2552411
- Transl Clin Pharmacol.
- 2023 Jun;31(2):105-113.
- doi: 10.12793/tcp.2023.31.e10
Two open-label, randomized, two-period crossover studies were conducted to investigate the pharmacokinetic (PK) properties, safety, and bioequivalence of the test formulation (KD4004), a new fixed-dose combination (FDC) formulation of dapagliflozin... -
- CITED
-
- Close
- SHARE
-
- Close
